IRON: Promising data and efficient trial execution position both DISC-3405 and bitopertin for strong market entry
DISC-3405 shows promising efficacy and safety in PV, with rapid trial progress and potential for frontline use. Bitopertin's APOLLO phase III trial is well-powered and targets a rare disease market, with launch strategies focused on engaged patients and centers of excellence. Oral therapies are exp…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.